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ABSTRACT
The pathogenesis of the adrenocortical cancer (ACC) involves integration of 
molecular signals and the interplay of different downstream pathways (i.e. IGFII/
IGF1R, β-catenin, Wnt, ESR1). This tumor is characterized by limited therapeutic 
options and unsuccessful treatments. A useful strategy to develop an effective therapy 
for ACC is to identify a common downstream target of these multiple pathways. A good 
candidate could be the transcription factor estrogen-related receptor alpha (ERRα) 
because of its ability to regulate energy metabolism, mitochondrial biogenesis and 
signalings related to cancer progression.
In this study we tested the effect of ERRα inverse agonist, XCT790, on the 
proliferation of H295R adrenocortical cancer cell line. Results from in vitro and 
in vivo experiments showed that XCT790 reduced H295R cell growth. The inhibitory 
effect was associated with impaired cell cycle progression which was not followed 
by any apoptotic event. Instead, incomplete autophagy and cell death by a necrotic 
processes, as a consequence of the cell energy failure, induced by pharmacological 
reduction of ERRα was evidenced.
Our results indicate that therapeutic strategies targeting key factors such as 
ERRα that control the activity and signaling of bioenergetics processes in high-
energy demanding tumors could represent an innovative/alternative therapy for the 
treatment of ACC.
INTRODUCTION
Adrenocortical carcinoma (ACC) is a very rare and 
aggressive disease with a high risk of relapse after radical 
surgery. Treatment options in advanced, metastatic stages 
are limited, since cytotoxic chemotherapy options are poor 
and radiotherapy is mostly ineffective [1]. The drug mitotane 
(o, p′-dichlorodiphe nyldichloroethane (o, p′-DDD)) with its 
adrenolytic activity is the only adrenal specific drug that 
is currently used for ACC treatment. However, toxicity, 
narrow therapeutic window and side effects are the major 
limitation to its use as well as therapeutic success [2]. 
Given the high mortality and aggressiveness of ACC, more 
effective and specific treatment options are needed. Recently, 
monoclonal antibodies targeting insulin-like growth factor II 
(IGFII) receptor (IGF1R) have been tested in clinical trials, 
however they provided a limited effectiveness in refractory 
patients [3]. Rationale for targeting IGF1R comes from the 
observation that IGFII gene is overexpressed in ACC [4]. We 
have recently demonstrated that IGFII/IGF1R pathway can 
be activated by the estrogen receptor alpha (ESR1), a gene 
overexpressed in ACC that mediates estrogen-dependent 
proliferative effects [5, 6]. ESR1 knock down was more 
effective than an IGF1R antibody in reducing H295R cell 
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proliferation in vitro [5] and the selective estrogen receptor 
modulator (SERM) tamoxifen prevented the growth of 
H295R both in vitro [7] and as xenografts in vivo [5]. Thus, 
ESR1 could be a promising target to reduce ACC growth.
Indeed, a recent study [8], investigating a large 
cohort of advanced ACC, confirmed the presence of a 
large number of potentially targetable molecules involved 
in ACC progression. These observations confirm that 
ACC is an extremely heterogeneous disease and that 
its pathogenesis involves integration of signals and the 
interplay of downstream pathways. It is currently accepted 
that these changes are also associated with a profound 
reprogramming of cellular metabolism [9]. Consequently, 
one potential strategy to develop an effective therapy for 
ACC could be the identification of a common downstream 
target of multiple pathways capable of controlling 
expression and activity of various bioenergetic factors.
Estrogen Related Receptor α (ERRα) is an orphan 
member of the nuclear hormone receptor superfamily of 
transcription factors that has been identified on the basis 
of its high level of sequence identity to ERα and for which 
an endogenous ligand has yet to be defined [10]. ERRα 
functions downstream of the peroxisome proliferator-
activated receptor gamma coactivator-1 alpha and beta 
(PGC-1α and PGC-1β) and regulates the expression of 
genes involved in energy metabolism and mitochondrial 
biogenesis such as genes encoding enzymes and proteins 
of the tricarboxylic acid cycle, pyruvate metabolism, 
oxidative phosphorylation, and electron transport [11]. 
Research to understand how changes in cell metabolism 
promote tumor growth has accelerated in recent years 
[12]. As a consequence, research has focused on targeting 
metabolic dependencies of cancer cells, an approach 
with the potential to have a major impact on patient 
care. Notably, ERRα has recently been associated with 
dysregulated cell metabolism and cancer progression. 
Accordingly, increased expression of ERRα has been 
shown in several cancerous tissues including breast [13], 
ovary [14] prostate [15] and colon [16]. Several signaling 
pathways, also relevant to ACC development have been 
shown to converge upon and regulate the expression and 
activity of ERRα together with its coactivators such as 
PGC-1α and β in others tumor types [17]. Several studies 
have reported that ERRα inverse agonist XCT-790 [18] 
can induce cell growth arrest in different tumor cell lines 
[19, 20]. To date, few studies have investigated the role 
of ERRα in adrenal gland and ACC. ERRα is expressed 
in normal adult adrenal and regulates the expression of 
enzymes involved in steroidogenesis [21]. Moreover, 
ERRα seems to be more expressed in ACC compared to 
normal adrenal and adenoma [22].
The aim of this study was to establish if ERRα 
depletion using XCT790 can induce growth arrest in 
ACC cells. The data obtained support the hypothesis that 
ERRα could be a promising target for the treatment of 
adrenocortical cancer.
RESULTS
ERRα inverse agonist XCT790 decreases 
ERRα protein content and inhibits ACC cells 
proliferation in vitro
First, we verified that ERRα is expressed in H295R 
adrenocortical cancer cells. MCF-7 breast cancer cells 
were used as positive control [23] (Figure 1A). Moreover, 
we also demonstrated that in both H295R and MCF-7 
cells, XCT790 treatment decreased ERRα protein levels 
in a dose-dependent manner (Figure 1B). The latter results 
confirmed the ability of XCT790 to reduce the expression 
of ERRα most probably by proteasome degradation [23]. 
Next, we evaluated the effects of different concentrations 
of ERRα inverse agonist XCT790 on ACC cell growth. 
Results from MTT assay revealed that XCT790 treatment 
exerted a dose- and time-dependent inhibition on H295R 
cell proliferation compared to vehicle-treated cells 
(Figure 1C). The maximum inhibitory effect on ACC cell 
proliferation was seen at 10 μM XCT790 that was then 
used for all the following experiments.
ERRα inverse agonist XCT790 inhibits ACC 
cells proliferation in vivo
We next established H295R cell xenograft tumors 
in immunocompromised mice to investigate the ability 
of XCT790 to reduce tumor growth in vivo. To this aim, 
H295R cells were injected into the intrascapular region 
of mice. When tumors reached an average volume of 
200 mm3, animals were randomized into two groups to 
be treated with either vehicle or XCT790 (2,5 mg/Kg). 
As shown in Figure 2A, mice treated with XCT790 
displayed a significant tumor growth reduction compared 
to the vehicle treated control group. Accordingly, tumor 
reduction upon XCT790 treatment is evidenced both in 
terms of tumor mass (Figure 2B) and proliferation as seen 
in Figure 2C, showing a strong decrease in Ki67staining 
(value score control: 7.2 ± 0,46 (SD); value score XCT790 
treated cells: 4.7 ± 0.53* (SD), *p < 0.05).
ERRα inverse agonist XCT790 blocks G1/S 
transition of ACC cells without inducing 
apoptosis
The observed effects of XCT790 on ACC cells 
proliferation led us to evaluate XCT790 action on H295R 
cell cycle progression.
First, by analyzing PI staining with FACSJazz flow 
cytometer, we investigated whether XCT790 treatment 
could affect the distribution of cells within the three 
major phases of the cycle. To this aim, H295R cells were 
grown for 24 h in 5% CS-FBS and then treated with either 
vehicle (DMSO) or 10 μM XCT790. 48 hours later, FACS 
analysis revealed that XCT790 treated cells accumulated 
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Figure 1: ERRα inverse agonist XCT790 decreases ERRα protein content and H295R cells growth in vitro. A. Western 
blot analysis of ERRα was performed on 50 μg of total proteins extracted from H295R and MCF-7 cells. Blots are representative of three 
independent experiments with similar results. (B. lower left and right panel), protein extracts from MCF-7 and H295R cells left untreated 
(–) or treated for 48 h with different doses of XCT790 were resolved by SDS-PAGE and subjected to immunoblot against ERRα. GAPDH 
served as loading control. (b, upper left and right panel), graphs represent means of ERRα optical density (O.D.) from three independent 
experiments with similar results normalized to GAPDH content (*p < 0.001 compared to untreated control sample assumed as 100). C. Cell 
viability after XCT790 treatment was measured using MTT assay. Cells were plated in triplicate in 24-well plates and were untreated (Ctr) 
or treated with increasing concentrations of XCT790 for the indicate times in DMEM supplemented with 2,5% Charcoal-Stripped FBS. 
Absorbance at 570 nm was measured on a multiwell-plate reader. Cell viability was expressed as a percentage of control, (*p < 0.001).
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in the G0/G1-phase of the cell cycle while the fraction of 
cells in S phase decreased compared with vehicle treated 
cells (Figure 3A).
In order to define the molecular mechanisms 
involved in XCT790-dependent cell cycle arrest, changes 
in levels of protein involved in cell cycle regulation 
were investigated by Western blotting analysis. After 
48 h treatment, XCT790 reduced Cyclin D1 and Cyclin 
E protein content while expression levels of CDK2 and 
CDK4 proteins were unaffected. Consistently with the 
observed G1/S transition arrest of the cell cycle, Rb 
protein showed a hypophosphorylated status (Figure 3B–
3C). As the analysis of the cell cycle revealed a minimal 
increase of the sub-G1 fraction (Figure 3A), a known 
Figure 2: ERRα inverse agonist XCT790 decreases H295R cells proliferation in vivo. A. 6 × 106 H295R cells were injected 
subcutaneously onto the intrascapular region of immunocompromised mice and the resulting tumors were grown to an average of 200 mm3. 
The animals were randomized to vehicle controls or XCT790 treatment for twenty one days. Tumor volumes were calculated, as indicated 
in Materials and Methods. Values represent the mean ± SE of measured tumor volume over time in the control group (filled circles, n = 10) 
and in the XCT790-treated group (filled squares, n = 10). B. After 21 days (3 weeks) tumors were harvested and weighed. Values represent 
the mean ± SE of measured tumour weight (n = 10) *P < 0.05 versus control at the same day of treatment. C. Ki67 immunohistochemical 
and H & E staining: histologic images of H295R explanted from xenograft tumors (magnification X 400).
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Figure 3: ERRα inverse agonist XCT790 impairs G1/S transition of ACC cells without inducing apoptosis. A. The 
distribution of H295R cells in the cycle was determined by Flow Cytometry using Propidium-iodide (PI) stained nuclei. The graph shows 
the distribution of H295R cell population (%) in the various phases of cell cycle. B. Total proteins from H295R cells left untreated (–) or 
treated with XCT790 for 48 h were resolved by SDS-PAGE and subjected to immunoblot analysis using specific antibodies against human 
Cyclin D1, Cyclin E, cdk2, cdk4, p-Rb. C. Graphs represent means of Cyclin D1, Cyclin E, cdk2, cdk4, p-Rb optical densities (O.D.) from 
three independent experiments with similar results normalized to GAPDH content, (*p < 0.001 compared to each untreated control assumed 
as 100); D. Total proteins were analyzed by Western blot for PARP-1. Blots are representative of three independent experiments with similar 
results. GAPDH served as loading control. E. Cellular caspase 3/7 activity was determined by Caspase-Glo assay system using the substrate 
Ac-DEVD-pNA and expressed as relative luminescence units (RLU) of treated cell to untreated control cell. Each column represents the 
mean ± SD of three independent experiments (*p < 0.001 compared to untreated control sample).
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marker of apoptotic events, we next attempted to verify 
the presence of apoptotic features such as PARP-1cleavage 
and caspase 3/7 activation, all well-known biochemical 
markers of programmed cell death. Surprisingly, results 
from Western blotting analysis for PARP-1 (Figure 3D) 
and caspase 3/7 activity assay (Figure 3E) clearly showed 
that XCT790 did not activate an apoptotic pathway.
XCT-790 decreased mitochondrial mass and 
function in ACC cells
The activity of ERRα is highly dependent on the 
presence of coactivator proteins, most notably PGC-1α 
and PGC-1β [24], both known for their crucial role in 
regulating energy metabolism and mitochondrial biogenesis 
[24]. Moreover, it has been observed that XCT790 
treatment, causing ERRα proteasome degradation, also 
down-regulates PGC1-α [24]. Based on these observations, 
we first checked if XCT790 treatment regulates PGC1-α 
expression in H295R cells. To this aim, ACC cells were 
left untreated or treated with 10 μM XCT790 for 48 h. 
Results from Western blotting showed (Figure 4A–4B) 
that XCT790 treated cells display a reduced expression of 
PGC1-α, with no effect on PGC-1β levels. We then asked 
whether reduced levels of PGC1-α would lead to reduction 
of mitochondrial mass. To this purpose we treated cells 
with MitoTracker deep red FM that stains specifically 
mitochondria independently of their membrane potential. 
Using flow cytometric analysis (Figure 4C), fluorescent 
imaging (Figure 4D) and fluorescent plate reader (Figure 
4E), we found that XCT790 significantly decreased 
mitochondrial mass.
The mitochondrial citrate carrier CIC is a protein 
that belongs to a family of metabolites transporters 
embedded in the inner mitochondrial membrane [25, 26] 
and has been recently highlighted as important component 
in maintaining mitochondrial integrity and bioenergetics 
in normal and particularly in tumor cells [27]. We used 
CIC protein expression as a marker of both mitochondrial 
mass and function and found that XCT790 decreased 
mitochondrial CIC expression (Figure 4F–4G) as well as 
its transport activity (Figure 4H) in H295R-treated cells 
compared to vehicle-treated control cells.
To extend these findings, we used immunoblotting 
to monitor the abundance of a known reliable marker 
of mitochondrial mass, TOM20, in response to 10 μM 
XCT790 treatment. We found that XCT790 treated-
H295R cells displayed a reduced expression of ERRα, as 
expected, concomitantly with a drastic decline of TOM20 
protein expression (Figure 5A–5B). Similarly, the analysis 
of the expression of the mitochondrial oxidative pathway 
(OXPHOS) enzymes showed a substantial reduction of 
all the complexes (Figure 5C). In agreement with these 
findings, the reduction in the ATP content reveals a 
bioenergetics failure induced by XCT790 in treated cells 
(Figure 5D).
XCT790 induce cell death by necrosis in ACC 
cells
Very recent data revealed that low levels of CIC or 
its impaired expression induce mitochondrial dysfunction 
followed by enhanced mitochondrial turnover via 
autophagy/mitophagy mechanism [27]. Based on this 
observation and accordingly to our above reported 
results showing the ability of XCT790 to down-regulate 
CIC expression in H295R cells, we wanted to verify if 
autophagic features were detected in our experimental 
conditions. Autophagy is characterized by acidic vacu-
oles (AVO) formation, which can be measured by 
acridine orange (AO) vital staining. AO moves freely to 
cross biological membranes and accumulates in acidic 
compartment, where it is seen as bright red fluorescence 
[28]. As shown in Figure 6A (upper panel), AO vital 
staining of 48 h XCT790-treated H295R cells showed the 
accumulation of AVO in the cytoplasm. To quantify the 
accumulation of the acidific component, we performed 
FACS analysis of acridine orange-stained cells using FL3 
mode (> 650 nm) to quantify the bright red fluorescence 
and FL1 mode (500–550 nm) for the green fluorescence. 
As shown in Figure 6A (lower panel), XCT790 treatment 
raised the strength of red fluorescence from 7,5% to 
51%. These results corroborate the observation that 
XCT790, increases the formation of AVOs which suggests 
autophagy/mitophagy as possible mechanisms to explain 
the reduced mitochondrial mass. This latter event could 
be responsible for the inhibitory effects on cell growth 
elicited by XCT790 on adrenocortical cancer cells. 
A careful evaluation of the autophagic/mitophagic process 
by investigating changes in autophagic markers such as 
Beclin 1, LC3B, BNIP3 and Cathepsin B (Figure 6B), 
suggested that XCT790 treatment promotes the initial 
stages of the autophagic process. This is supported by the 
evidence of increased Beclin 1 expression and the presence 
of the cleaved LC3B form [29]. However, autophagy fails 
to terminate as indicated by decreased BNIP3, Cathepsin 
B and Lamp1 proteins expression [29]. Therefore, we 
evaluated XCT790 ability to induce H295R cells death 
by necrosis. To this aim, Trypan blue exclusion test was 
performed after 48 h of XCT790 treatment. As shown in 
Figure 6C, H295R displayed a significant increase in the 
number of positive stained cells compared to control cells 
indicating that membrane integrity and permeability were 
lost accounting for a necrotic event following a bionergetic 
failure triggered by ERRα depletion.
DISCUSSION
The molecular heterogeneity and complexity that 
characterize adrenocortical cancer biology combined 
with lack of an effective treatment, drive towards the 
discovery of new therapeutic targets. Advances in the 
understanding of the molecular pathogenesis of ACC have 
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Figure 4: XCT-790 decreases mitochondrial mass and function in H295R cells. A. Total protein extracts from H295R cells, left 
untreated (–) or XCT790 treated in 2.5% DCC-FBS medium for 48 h were analyzed by Western blot with antibodies against PGC-1α and 
PGC-1β. GAPDH was used as loading control. B. Graphs represent means of PGC-1α and β optical densities (O.D.) from three independent 
experiments with similar results normalized to GAPDH content (*p < 0.001 compared to each untreated control sample assumed as 100).  
C. H295R cells were right untreated (control) or treated with XCT790. 48 h later, absorption of MitoTracker deep red FM was determined 
by FACS analysis. The uptake of MitoTracker was used as an indicator for the mitochondrial mass. D. Reduction in mitochondrial mass was 
further evaluated by fluorescence microscopy of MitoTracker-stained cells. E. Quantification of Mito-Tracker fluorescent signal intensity in 
untreated (control) or XCT790-treated H295R cells was evaluated measuring red fluorescent signal by a fluorescent plate reader (ex. 644; 
em. 665) *p < 0,001 compared to untreated control sample. F. Immunoblots for CIC expression from mitochondrial extracts in untreated 
(–) or XCT-790 treated H295R cells for 48 h. β-Actin served as loading control. Blots are representative of three independent experiments 
with similar results. G. Graph represent means of CIC density (O.D.) from three independent experiments with similar results normalized 
to β-Actin content (*p < 0.001 compared to untreated control sample assumed as 100). H. CIC activity was measured at 20 min as steady-
state levels of citrate/citrate exchange. Transport was started by adding 0.5 mM [14C]Citrate to proteoliposomes preloaded internally with 
10 mM citrate and reconstituted with mitochondria isolated from untreated H295R cells (Control; white column) and H295R-treated cells 
(black column). The transport reaction was stopped at 20 minutes. Results are expressed as percentage of the control. The data represent 
means ± SD of at least three independent experiments.
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been made based on studies of gene expression profiling 
and genetic syndromes associated with the development 
of ACC [30]. Results from these studies have highlighted 
the presence of different and important modifications 
such as somatic TP53 mutations, alterations at 11p15, a 
chromosomal locus of IGFII, H19 and cyclin-dependent 
kinase inhibitor 1C, β-catenin accumulation and activation 
of the Wnt signaling pathway and overexpression of SF-1 
protein [30]. Moreover we have recently demonstrated the 
involvement of ESR1 in ACC cell growth regulation [5]. 
Genetic modifications and molecular pathways alterations 
have as a common purpose the survival and proliferation 
of the transformed phenotype. It is currently accepted that 
these changes are associated with a concurrent adaptation 
and reprogramming of cellular metabolism [31]. In this 
scenario adrenocortical tumors are not an exception and 
the metabolic receptor ERRα represents a good therapeutic 
target. In fact, ERRα is a common downstream target of 
multiple pathways and a key factor in controlling the 
expression and activity of various bioenergetics processes. 
Indeed, it has already been observed that high ERRα gene 
expression correlates with unfavorable clinical outcomes 
Figure 5: XCT790 decreased OXPHOS protein content and ATP concentration in H295R cells. A. Total protein extracts 
from H295R cells, left untreated (–) or treated for 48 h in 2.5% DCC-FBS medium with 10 μM XCT790, were analyzed by Western blot 
using antibodies against ERRα and TOM20. β-actin was used as loading control. B. Graphs represent means of ERRα and TOM20 optical 
densities (O.D.) from three independent experiments with similar results normalized to β-Actin content (*p < 0.001 compared to each 
untreated control sample assumed as 100). C. Total protein extracts from H295R cells left untreated (–) or treated for 48 h in 2.5% DCC-
FBS medium with 10 μM XCT790, were analyzed by Western blot experiments using antibodies against OXPHOS subunits. β-Actin was 
used as loading control. Blots are representative of three independent experiments with similar results. D. ATP concentrations in H295R 
cells untreated (–) or treated with XCT790 were determined as described in Material and Methods and expressed as nmol/number of cells. 
Each column represents the mean ± SD of three independent experiments (*p < 0, 001).
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in breast [32] and ovarian cancer [14, 33] and that breast 
cancer cells exhibiting high ERRα activity are more 
sensitive to growth inhibition by an ERRα inverse agonist 
such as XCT790 [34]. Consistent with this findings and 
with very recent data reporting high ERRα expression in 
adrenal tumors compared to benign and normal adrenal 
gland [22], here we report that ERRα is expressed in 
H295R cells, the most valid cell model to study ACC 
Figure 6: XCT790 induces necrosis in H295R cells. A. H295R cells were left untreated (control) or treated with XCT790 10 μM. 
After 48 h, cells were incubated with (1 μg/mL) acridine orange (AO) solution for 30 min at 37°C. Absorption of AO was determined by 
FACS analysis (lower panel). In the same experimental conditions, treated or untreated H295R cells were stained with acridine orange, 
mounted and immediately analyzed by fluorescent microscope (upper panel). B. Total protein extracts from H295R cells left untreated (–) 
or treated in 2.5% DCC-FBS medium with XCT790, as indicated, for 48 h were analyzed by Western blot experiments using antibodies 
against Beclin 1, LC3B, BNIP3, Cathepsin B, Lamp1. β-Actin was used as loading control. Blots are representative of three independent 
experiments with similar results. C. Cell death by necrosis was assessed by Trypan blue-exclusion assay in H295R cells untreated (–) or 
treated with XCT790. The mean ± SD of three replicates are shown. Cell death was expressed as a percentage of control, (*p < 0.001).
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biology. Moreover, our data show that pharmacological 
down-regulation of ERRα expression impaired H295R cell 
proliferation in vitro in a dose-dependent fashion. Most 
importantly, the same inhibitory effect was obtained also in 
in vivo experiments using H295R cells as xenograft model. 
At the molecular level, the growth inhibition is associated 
with a G0/G1 cell cycle arrest and by the decreased levels 
of G1-phase markers such as Cyclin D1 and pRb while 
CDKs protein levels were unaffected. Noteworthy, cell 
cycle arrest was not followed by any apoptotic event since 
we were unable to detect any morphological data (data not 
shown) or biochemical events such caspase activation and 
PARP-1 cleavage.
Accumulating data provide evidence that a 
caspase-independent form of programed cell death such 
as autophagy can be at play under certain conditions 
[35]. Therefore we investigated whether the inhibitory 
effects induced by XCT790 treatment could be linked 
to autophagy. Our results indicated that XCT790 
caused a significant increase in autophagic vesicles. 
Conco mitantly, we observed a drastic reduction in 
the expression of PGC1-α protein, which plays a key 
role in mitochondrial biogenesis, and of mitochondrial 
carrier CIC. The reduction of mitochondrial mass, also 
confirmed by the reduction of TOM20 protein expression, 
is followed by a considerable and significant decrease 
in the ATP concentration. Despite the presence of some 
autophagic markers such as the up-regulation of Beclin 1 
and the cleaved form of LC3 protein, the formation of 
autophagolysosomes seems to be incomplete as evidenced 
by the reduction in LAMP1 protein, known to play an 
important role during the final steps of autophagy process 
[36]. A possible explanation could be a considerable 
reduction in the availability of intracellular ATP, required 
to drive forward the active cell death mechanism 
including autophagy. On the other hand, we cannot 
exclude that the observed initial steps of autophagy are 
a defense cell response to keep cells alive during energy 
failure to counteract the reduced expression and activity 
of the master bioenergetic executor ERRα. Moreover, 
the bioenergetics crisis following treatment with ERRα 
inverse agonist might be responsible for the loss of plasma 
membrane integrity, a key signature for a necrotic cell 
death, allowing the significant increase in the number of 
Trypan blue stained cells.
However, our most significant finding is that in 
ACC cells ERRα depletion after XCT790 treatment 
clearly caused a reduction of mitochondrial function and 
mass leading to the activation of a number of cellular 
mechanisms that result in tumor cell death.
It’s now well known that mitochondria with its 
direct involvement in bioenergetics, biosynthesis and cell 
signaling are mandatory for tumorigenesis. Thus, it’s not 
surprising that many studies have begun to demonstrate 
that mitochondrial metabolism and signaling is potentially 
a successful avenue for cancer therapy. Moreover, ACC 
is (in most cases) characterized by steroids producing/
secreting cancer cells highly dependent on functioning 
mitochondria to ensure steroidogenic processes. For 
these reasons, strategies using mitochondrial metabolism 
and signaling as targets should be particularly effective 
for ACC treatment. Moreover, our current data obtained 
performing in vivo experiments by using H295R cells as 
xenograft model and according to previous in vivo studies 
performed in breast [37] and leukemia [38] tumor cells 
also suggest that chemical depletion of ERRα may be 
specific for high energy demanding cells such as tumor 
cells without exerting any toxic effect on other tissues.
In conclusion, our study supports the hypothesis that 
ERRα represents a valid innovative/alternative target for 
the treatment of adrenocortical cancer.
MATERIALS AND METHODS
Cell culture
H295R adrenocortical cancer cells were obtained 
from Dr. Antonio Stigliano (University of Rome, Italy) 
and cultured in DMEM/F12 supplemented with 1% ITS 
Liquid Media Supplement, 10% fetal bovine serum (FBS), 
1% glutamine, 2% penicillin/streptomycin (complete 
medium). MCF7 breast cancer cells were maintained in 
monolayer cultures DMEM/F12. supplemented with 10% 
FBS, 1% glutamine, 2% penicillin/streptomycin. Both cell 
lines were cultured at 37°C in 5% CO2 in a humidified 
atmosphere. All media and supplements were from Sigma-
Aldrich, Milano, Italy.
Western blot analysis
Whole cell lysate were prepared in RIPA buffer (50 
mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 2 mM sodium fluoride, 2 mM EDTA, 
0.1% SDS and a mixture of protease inhibitors) or in 
ice-cold lysis buffer (10 mM Tris-HCl pH 8, 150 mM 
NaCl, 1% Triton X-100, 60 mM octylglucoside). Samples 
were analyzed by 11% SDS-PAGE and blotted onto a 
nitrocellulose membrane. Blots were incubated overnight 
at 4°C with anti-ERRα polyclonal antibody, anti-cyclin 
D1, anti-cyclin E, anti-cdk2, anti-cdk4, anti-p-Rb, anti-
PARP, anti-cathepsin B, anti-LAMP1, anti-Tom20 (all 
from Santa Cruz Biotechnology), anti-Beclin 1 (Novus 
Biological), anti-LC3B antibody, anti-BNIP3 antibody, 
Mitoprofile Total OXPHOS Human WB Antibody 
Cocktail (Abcam) and then incubated with appropriate 
horseradish peroxidase conjugated secondary antibodies 
for 1 h at room temperature. The immunoreactive products 
were detected by the ECL Western blotting detection 
system (Amersham Pharmacia Biotech, Piscataway, NJ). 
GAPDH antibody (Santa Cruz Biotechnology) or anti-




H295R cells were seeded in 12-well plates at a 
density of 1 × 105 cells per well and cultured in complete 
medium overnight. Before treatment culture medium was 
switched into in DMEM F-12 supplemented with 2.5% 
charcoal stripped (CS) FBS and cells were untreated or 
treated with different concentration of XCT790 (Tocris 
Bioscience, Bristol, UK) for the indicated time. DMSO 
(Sigma-Aldrich) was used as vehicle control. Cell viability 
was measured using MTT assay (Sigma-Aldrich). Each 
experiment was performed in triplicate and the optical 
density was measured at 570 nm in a spectrophotometer. 
Experiments were repeated three times.
Trypan blue assay
Trypan blue stain was prepared freshly as a 0.4% 
solution in 0.9% sodium chloride before each experiment. 
After trypsinization, 20 μl cell suspension was added 
to 20 μl of Trypan blue solution and mixed thoroughly. 
Triplicate wells of dye positive cells from untreated or 
XCT790 treated were counted using a hemocytometer and 
the experiment was repeated three times.
Xenograft model
Athymic Nude- Foxn1nu mouse 4–6 weeks old) 
from Charles River Laboratories [Calco (LC), Italy] were 
maintained in groups of five or less and quarantined for 
one week. Mice were kept on a 12 h light/dark cycle with 
ad libitum access to food and water.
6 × 106 H295R cells suspended in 100 μl of sterile 
PBS (Dulbecco's Phosphate Buffered Saline) and mixed 
with 100 μl of matrigel, were injected subcutaneously 
into the intrascapular region of each animal. When tumor 
size reached a volume of about 200 mm3 mice were 
randomly divided in 2 groups. Animals were injected 
every other day with vehicle (soy oil) or XCT790 (2,5 
mg/Kg) over a 21 day period. Tumors were measured 
with a caliper every two days, volumes were calculated 
using the formula V = a b2/2 (V:volume; a is the length of 
the long axis, and b is the length of the short axis. At the 
end of the treatment period tumors were harvested and 
tumor weight and volumes were evaluated. All animal 
procedures were approved by the local Ethics Committee 
for Animal Research.
Immunohistochemical analysis
5 μm thick paraffin-embedded sections were mo-
unted on slides precoated with poly-lysine, and then 
they were deparaffinized and dehydrated (seven to eight 
serial sections). Immuno-histochemical experiments 
were performed using rabbit polyclonal Ki67 primary 
antibody (Dako, Denmark ) at 4°C over-night. Then, 
a biotinylated goat-anti-rabbit IgG was applied for 
1 h at room temperature, followed by avidin biotin-
horseradish peroxidase reaction (Vector Laboratories, 
CA). Immunoreactivity was visualized by using 
the diaminobenzidine chromogen (Sigma-Aldrich). 
Counterstaining was carried out with methylene-blue 
(Sigma-Aldrich). Hematoxylin and eosin Y staining was 
performed as suggested by the manufacturer (Bio-Optica, 
Milan, Italy).
Scoring system
The immunostained slides of tumor samples were 
evaluated by light microscopy using the Allred Score 
[39] which combines a proportion score and an intensity 
score. A proportion score was assigned representing the 
estimated proportion of positively stained tumor cells (0 = 
none; 1 = 1/100; 2 = 1/100 to <1/10; 3 = 1/10 to <1/3; 4 = 
1/3 to 2/3; 5 = >2/3). An intensity score was assigned by 
the average estimated intensity of staining in positive cells 
(0 = none; 1 = weak; 2 = moderate; 3 = strong). Proportion 
score and intensity score were added to obtain a total score 
that ranged from 0 to 8. A minimum of 100 cells were 
evaluated in each slide. Six to seven serial sections were 
scored in a blinded manner for each sample.
Cell cycle analysis
H295R cells treated with different doses of XCT790 
were fixed, treated with RNase A (20 μg/ml), stained 
with Propidium iodide (100 μg/ml) (Sigma-Aldrich) and 
analyzed by Flow Cytometry using BD FACSJazz™ Cell 
Sorter (Becton, Dickinson and Co) for DNA content and 
cell cycle status.
Caspases 3/7 activity assay
Caspases activity was measured with Caspase-Glo 
Assay Kit (Promega Italia SRL, Milano, Italy) following 
the manufacturer instruction. The luminescence of each 
sample was measured in a plate-reading luminometer 
(Gen5 2.01) with Synergy H1 Hybrid Reader. Each 
experiment was performed on triplicate wells per 
condition.
Mitochondrial mass determination
XCT790 treated or untreated H295R cells 
were incubated in serum free medium with 200 nM 
Mitotracker deep red (Invitrogen, USA) for 30 min 
at 37°C in the dark. After staining, cells were washed 
twice with cold PBS, trypsinized, centrifuged at 1200 
rpm for 5 min and then resuspended in PBS. Absorption 
of MitoTracker deep red FM was determined by FACS 
analysis and by fluorescence microscopy. In the same 
experimental conditions, fluorescent signal intensity 
was also assessed using a fluorescent plate reader (ex. 
644 nM; em. 665 nM).
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Detection of acidic vesicular organelles (AVOs) 
with acridine orange
H295R cells were cultured on 6 well plates and 
treated in 2.5% CS-FBS with or without 10 μM XCT790. 
After 48 h, cells were washed with PBS and stained for 
30 min at 37°C with 1 μg/mL acridine orange solution 
(Sigma-Aldrich). Cells were then washed three times with 
cold PBS and one drop of mounting solution was added. 
Cell were observed and imaged by an inverted fluorescence 
microscope (100X magnification). Accumulation of the 
acidic vacuoles was also determined by FACS analysis.
ATP Determination
1 × 105 cells were seeded in 96 white clear bottom 
multi-well plates in complete medium. Two days later, 
cells were treated in DMEM F-12 supplemented with 
2.5% CS FBS containing 10 μM XCT790. After 48 h, 
ATP concentrations were determined using the CellTiter-
Glo luminescent cell viability assay (Promega) following 
the manufacturer instruction. Results were normalized to 
the cell number evaluated by HOECHST staining (Sigma-
Aldrich) and expressed as nMol/number of cells.
Mitochondria reconstitution and transport 
measurements
The transport activity was carried out as described 
previously [40]. Briefly, isolated mitochondria from 
untreated (control) or XCT790 treated H295R cells were 
solubilized in a buffer containing 3% Triton X, 114, 4 mg/ml 
cardiolipin, 10 mM Na2SO4, 0.5 mM EDTA, 5 mM PIPES 
pH 7. The mixture was incubated for 20 min and centrifuged 
at 138,000 × g for 10 min. The supernatant was incorporated 
into phospholipid vesicles by cyclic removal of the detergent 
[41]. The reconstitution mixture consisted of 0.04 mg 
protein solution, 10% Triton X-114, 10% phospholipids (egg 
lecithin from Fluka, Milan, Italy) as sonicated liposomes, 
10 mM citrate, 0.85 mg/ml cardiolipin (Sigma) and 20 
mM PIPES, pH 7.0. The citrate transport was measured 
after external substrate removal from proteoliposomes on 
Sephadex G-75 columns, pre-equilibrated with buffer A 
(50 mM NaCl and 10 mM PIPES, pH 7.0). Transport at 
25°C was started by the addition of 0.5 mM [14C] citrate 
(Amersham) to the eluted proteoliposomes and terminated 
by the addition of 20 mM 1,2,3-benzene-tricarboxylate. 
Finally, the external radioactivity was removed from the 
Sephadex G-75 columns, liposomes radioactivity was 
measured and transport activity was calculated [41].
Statistics
All experiments were performed at least three 
times. Data were expressed as mean values ± standard 
deviation (SD), statistical significance between control and 
treated samples was analyzed using GraphPad Prism 5.0 
(GraphPad Software, Inc.; La Jolla, CA) software. Control 
and treated groups were compared using the analysis of 
variance (ANOVA). A comparison of individual treatments 
was also performed, using Student’s t test. Significance 
was defined as p < 0.05.
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